Antenatal Depression, Depression, Pregnancy Related
Conditions
Keywords
Depression, Pregnancy, Antidepressants, Mindfulness, Medication use during pregnancy, Depression Relapse, Suicidal ideation
Brief summary
The purpose of this investigation is to conduct a pragmatic effectiveness trial comparing digital mindfulness-based cognitive therapy (MBCT) plus usual care to usual care (UC) only among euthymic pregnant women with recurrent depression treated with antidepressants. In the supplemental arms we will investigate the prevalence, severity, longitudinal course, correlates, and predictors of suicidal ideation and behavior among women during pregnancy and the postpartum period.
Detailed description
This study will address a significant gap in the evidence regarding effective approaches to prevent depressive relapse among women with recurrent depression who maintain euthymia using antidepressants and who wish to conceive or who are pregnant. Relapse rates of depression following antidepressant discontinuation among such women has been established, and the efficacy of MBCT in mitigating relapse risk in pregnant women with recurrent depression compared to UC also has been demonstrated. But the effectiveness of MBCT has not been tested in a definitive trial; the question of whether MBCT can mitigate risk for depressive relapse among pregnant women on antidepressants, including among those who discontinue antidepressants proximate to or during pregnancy, also has not been addressed. Reproductive age women with recurrent depression and their healthcare providers need to know, first, if a scalable digital non-pharmacologic prevention approach is superior to UC in community settings, and second, whether MBCT can attenuate risk for depressive relapse among those who elect to discontinue maintenance antidepressant treatment proximate to or during pregnancy. Lastly, the capacity to identify which women are most likely to benefit from a non-pharmacologic or pharmacologic approach personalizes the risk benefit decision making process for reproductive age women on antidepressants planning to conceive or who are pregnant. Investigators will test the relative risk for depressive relapse and reduction of symptom burden between women randomized to digital MBCT or UC, explore the specific benefit of MBCT relative to antidepressant discontinuation, and determine whether a treatment selection algorithm can predict whether MBCT or UC will work best for a specific participant. The supplemental arms of this study will further investigate suicidal ideation and behavior in a perinatal population to better understand the prevalence, severity, longitudinal course, correlates and predictors of suicidal ideation and behavior among women during pregnancy and in the postpartum period. Investigators will use a mixed methods approach of both cross-sectional and longitudinal study designs to characterize a real-world population of pregnant and postpartum women who have endorsed suicidality. Investigators will also use qualitative interviews, self-report instruments, and medical records to explore the extent to which community healthcare professionals providing care to perinatal women report the knowledge base and requisite skills to address suicidal ideation and behavior in this population. MMB for Moms delivers digitally both the content and structure of in-person MBCT, and may be a promising intervention for pregnant women with suicidal ideation. Investigators will also explore the safety, feasibility, and acceptability of enrolling pregnant women with any reports of suicidal ideation or behavior in a proof of concept randomized controlled trial comparing MMB for Moms to enhanced usual care.
Interventions
12-week program that emphasizes mindfulness and cognitive behavioral skills
Sponsors
Study design
Eligibility
Inclusion criteria
* Pregnant women * Ages 18 or older * History of recurrent major depression prior to pregnancy (at least 2 prior episodes, one of which may be currently treated) * Euthymic or with residual symptoms (PHQ-9 ≤ 9) * No depressive relapse since last menstrual period * Currently or recently received antidepressants (within the three months prior to last menstrual period) * Presence of ongoing community provider
Exclusion criteria
* Diagnosis of bipolar or psychotic disorder * Active mania, psychosis, or substance abuse (within the last 6 months) * Immediate risk of self-harm * Non-English speaking Inclusion and
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Experiencing Relapse of Depression | Randomization through 6 months postpartum | Depression relapse from randomization through 6 month postpartum |
Countries
United States
Participant flow
Recruitment details
The UPWARD randomized clinical trial was conducted nationally, recruiting euthymic pregnant women with recurrent depression treated with antidepressants. Participant recruitment for UPWARD began March 7, 2019, and concluded July 8, 2020.
Pre-assignment details
745 individuals were eligible after the initial phone screen, 512 completed the baseline interview and surveys (66 were found ineligible during the baseline interview, 20 did not complete baseline surveys within 1 week, and 147 were non-responsive to follow-up), and 500 were randomized (12 were lost to follow up before randomization).
Participants by arm
| Arm | Count |
|---|---|
| Digital Delivery of MBCT (Mindful Mood Balance for Moms) Subjects will receive digital delivery of mindfulness-based cognitive therapy (Mindful Mood Balance for Moms) for 12 weeks, along with the usual care they would receive from their provider.
Digital Delivery of Mindfulness-Based Cognitive Therapy: 12-week program that emphasizes mindfulness and cognitive behavioral skills | 249 |
| Usual Care Subjects will receive only usual care, the care they would normally receive from their community provider, for 12 weeks. | 251 |
| Total | 500 |
Baseline characteristics
| Characteristic | Digital Delivery of MBCT (Mindful Mood Balance for Moms) | Usual Care | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 249 Participants | 251 Participants | 500 Participants |
| Age, Continuous | 32.1 years STANDARD_DEVIATION 4.65 | 32.2 years STANDARD_DEVIATION 4.43 | 32.2 years STANDARD_DEVIATION 4.54 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 17 Participants | 29 Participants | 46 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 232 Participants | 222 Participants | 454 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) Asian | 8 Participants | 9 Participants | 17 Participants |
| Race (NIH/OMB) Black or African American | 11 Participants | 14 Participants | 25 Participants |
| Race (NIH/OMB) More than one race | 5 Participants | 9 Participants | 14 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 3 Participants | 2 Participants | 5 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 4 Participants | 6 Participants | 10 Participants |
| Race (NIH/OMB) White | 216 Participants | 210 Participants | 426 Participants |
| Sex: Female, Male Female | 249 Participants | 251 Participants | 500 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 249 | 0 / 251 |
| other Total, other adverse events | 177 / 249 | 209 / 251 |
| serious Total, serious adverse events | 0 / 249 | 0 / 251 |
Outcome results
Number of Participants Experiencing Relapse of Depression
Depression relapse from randomization through 6 month postpartum
Time frame: Randomization through 6 months postpartum
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Digital Delivery of MBCT (Mindful Mood Balance for Moms) | Number of Participants Experiencing Relapse of Depression | 81 Participants |
| Usual Care | Number of Participants Experiencing Relapse of Depression | 111 Participants |